Induction of systemic lupus erythematosus with tumor necrosis factor blockers

Journal of Rheumatology

Volumn 37, Issue 1, 2010, Pages 204-205

  Soforo, Ekaterina ^a   Baumgartner, Manfred ^a   Francis, Lisa ^a   Allam, Fatme ^a   Phillips, Paul E ^a   Perl, Andras ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; CARDIOLIPIN ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ETANERCEPT; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

ABNORMAL RESPIRATORY SOUND; ADULT; ANTIBODY TITER; ARTHRITIS; BLURRED VISION; CLINICAL ARTICLE; DEPRESSION; DIZZINESS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; HEADACHE; HEMATOLOGIC DISEASE; HEMATURIA; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; IMMUNE COMPLEX NEPHRITIS; IMMUNOPATHOLOGY; INFLAMMATION; KIDNEY BIOPSY; KIDNEY DISEASE; LETTER; LEUKOCYTOSIS; MAJOR DEPRESSION; MENTAL HEALTH; MOUTH ULCER; NEUROLOGIC DISEASE; PAPULAR RASH; PARESTHESIA; PERICARDIAL EFFUSION; PERICARDITIS; PHOTOSENSITIVITY DISORDER; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEINURIA; PSORIATIC ARTHRITIS; RASH; RHEUMATOID ARTHRITIS; SIDE EFFECT; ST SEGMENT ELEVATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; THORAX RADIOGRAPHY; TREATMENT DURATION; UNSTEADINESS; WEAKNESS;

ANTIRHEUMATIC AGENTS; ARTHRITIS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 73649112364     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.081312     Document Type: Letter

References (9)

1. Imperato AK, Smiles S, Abramson SB. Long-term risks associated with biologic response modifiers used in rheumatic diseases. Curr Opin Rheumatol 2004;16:199-205.
2. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004;50:3161-9.
3. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007;86:242-51.
4. Panush RS, Edwards NL, Longley S, Webster E. 'Rhupus' syndrome. Arch Intern Med 1988;148:1633-6.
5. Hoffman IEA, Peene I, Cebecauer L, et al. Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus [letter]. Ann Rheum Dis 2005;64:330-2.
6. Kovacs B, Vassilopoulos D, Vogelgesang SA, Tsokos GC. Defective CD3-mediated cell death in activated T cells from patients with systemic lupus erythematosus: role of decreased intracellular TNF-alpha. Clin Immunol Immunopathol 1996;81:293-302.
7. Jacob CO, McDevitt HO. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature 1988;331:356-8.
8. Ma L, Chan KW, Trendell-Smith NJ, et al. Systemic autoimmune disease induced by dendritic cells that have captured necrotic but not apoptotic cells in susceptible mouse strains. Eur J Immunol 2005;35:3364-75.
9. Perl A, Gergely P Jr, Nagy G, Koncz A, Banki K. Mitochondrial hyperpolarization: a checkpoint of T cell life, death, and autoimmunity. Trends Immunol 2004;25:360-7.